Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB +0.48%85 5-Year Yield-on-Cost % is 3.79 as of Jul. 31, 2026, which is 11% above its 10-year median of 3.40. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT126.56 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 512 Drug Manufacturers companies, ACME Laboratories ranks better than 64.84% on this metric.
ACME Laboratories's yield on cost for the quarter that ended in Mar. 2026 was 3.79.
The historical rank and industry rank for ACME Laboratories's 5-Year Yield-on-Cost % or its related term are showing as below:
DHA:ACMELAB'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.09 Med: 3.4 Max: 5.42
Current: 3.79
During the past 9 years, ACME Laboratories's highest Yield on Cost was 5.42. The lowest was 2.09. And the median was 3.40.
DHA:ACMELAB's 5-Year Yield-on-Cost % is ranked better than 64.84% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs DHA:ACMELAB: 3.79
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
ACME Laboratories 5-Year Yield-on-Cost % Related Terms
DHA:ACMELAB vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
ACME Laboratories (DHA:ACMELAB) has a 5-Year Yield-on-Cost % of 3.79 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ACME Laboratories and its competitors. This is 11% above median its historical median of 3.40. Over the past decade, ACME Laboratories' 5-Year Yield-on-Cost % has ranged from 2.09 to 5.42. According to the industry distribution chart, ACME Laboratories ranks #180 out of 512 companies in the Drug Manufacturers industry, placing it in the top 35.2%.
Is ACME Laboratories' 5-Year Yield-on-Cost % too high?
ACME Laboratories' current 5-Year Yield-on-Cost % of 3.79 is 11% above median its 10-year median of 3.40. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 5.42. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. ACME Laboratories' value of 3.79 is 63.4% above this industry median. Based on the distribution chart, ACME Laboratories ranks #180 out of 512 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #180 out of 512 companies for 5-Year Yield-on-Cost %. This puts ACME Laboratories in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. ACME Laboratories' value of 3.79 is 63.4% above this benchmark. Historically, ACME Laboratories' own 5-Year Yield-on-Cost % has ranged from 2.09 to 5.42 over the past decade. While the company's 10-year median is 3.40 vs. the industry median of 2.32, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current 5-Year Yield-on-Cost % of 3.79 is 63.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current 5-Year Yield-on-Cost % is 3.79, which is 11% above median its own 10-year median of 3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.56, compared to a current price of BDT83.60 — trading 33.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.79, which is 11% above median its 10-year median of 3.40 and 63.4% above the Drug Manufacturers industry median of 2.32. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current 5-Year Yield-on-Cost % is 3.79 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT83.60 is trading 33.9% below its estimated GF Value™ of BDT126.56.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
5-Year Yield-on-Cost %: 3.79 (11% above median its 10-year median of 3.40)
GF Value™: BDT126.56 vs. price of BDT83.60 (33.9% below fair value)
Industry Position: 63.4% above the Drug Manufacturers median (#180 of 512)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
